Phase2 Prospective, Multi-center, Open-label, Controlled Trial to Assess the Safety and Efficacy of Cellular Immunotherapy with MDR-103 for Induction of Mixed Chimerism and Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kid
Clinical Trial Grant
Administered By
Surgery, Abdominal Transplant Surgery
Awarded By
Medeor Therapeutics, Inc
Start Date
December 11, 2018
End Date
May 4, 2021
Administered By
Surgery, Abdominal Transplant Surgery
Awarded By
Medeor Therapeutics, Inc
Start Date
December 11, 2018
End Date
May 4, 2021